Yahoo Finance

Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01

STOCKHOLM, SWEDEN January 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has secured SEK 205 million in a series A extension financing ...
Yahoo Finance

Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a ...
manilatimes

Karolinska Development's portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the ...
Finanznachrichten

KDventures AB: KDventures' portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval

STOCKHOLM, SWEDEN March 11, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has received approval for a US patent covering the use of AC01 for the ...
Finanznachrichten

Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a ...